Antihyperglycemic effects aside, GLP-1 RAs reduce gastric emptying and suppress appetite centres in the hypothalamus, resulting in weight loss
Notably, patients with both T2DM and overweight/obesity conditions experienced a significant ETD in HbA1c reduction (ETD = -0.14, p = 0.016), contrasted with the non-significant change in patients with T2DM only (ETD = 0.08, p = 0.719)
If digestive enzymes help with slow digestion, do they cancel out the GLP-1 benefit
Not recommended during pregnancy or breastfeeding
Using MK-677 during the CJC-1295 off period defeats the purpose
Across trials where participants lost at least 15% of their body weight, lean mass made up roughly 25% of total weight lost on tirzepatide and roughly 39% on semaglutide